Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States
Objective: To estimate health care costs associated with medical events identified as antiretroviral therapy (ART)-attributable adverse events (AEs). Methods: During September 2006 to June 2012, adults with ≥1 HIV International Classification of Diseases, Ninth Revision, Clinical Modification diagno...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-01-01
|
| Series: | Journal of the International Association of Providers of AIDS Care |
| Online Access: | https://doi.org/10.1177/2325957415594883 |
| _version_ | 1818035353946161152 |
|---|---|
| author | Mitch Dekoven MHSA Charles Makin BSPharm, MS, MBA, MM Samantha Slaff MS Michael Marcus MAS Eric M. Maiese PhD |
| author_facet | Mitch Dekoven MHSA Charles Makin BSPharm, MS, MBA, MM Samantha Slaff MS Michael Marcus MAS Eric M. Maiese PhD |
| author_sort | Mitch Dekoven MHSA |
| collection | DOAJ |
| description | Objective: To estimate health care costs associated with medical events identified as antiretroviral therapy (ART)-attributable adverse events (AEs). Methods: During September 2006 to June 2012, adults with ≥1 HIV International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code (042/V08), ≥1 claim for ART prescription (March 2007-June 2011; index date), and continuous health plan enrollment for ≥6 months pre- and ≥12 months postindex were included (IMS’ PharMetrics Plus Health Plan Claims Database). Patients with events of interest/ART claim during preindex period or with pregnancy/hepatitis C virus diagnosis/hepatitis B virus/cancer/tuberculosis during the study period were excluded. Postindex medical events were defined as first diagnosis code of event with ART claim ≤60 days prior to start of the event. Results: Differences in median total all-cause health care costs observed for diabetes/insulin resistance management (US$14 547 median all-cause health care costs during time periods identified as diabetes/insulin resistance medical events versus US$11 237 without diabetes/insulin resistance events; P = .0021), lipid disorders (US$12 825 versus US$10 033; P = .0004), and renal disorders (US$1389 versus US$0; P < .0001). Discussion/Conclusion: Health care costs of ART AEs should be key consideration for payers/providers in HIV management. |
| first_indexed | 2024-12-10T06:53:43Z |
| format | Article |
| id | doaj.art-6f90b3927a794269aecb9001b27f9649 |
| institution | Directory Open Access Journal |
| issn | 2325-9574 2325-9582 |
| language | English |
| last_indexed | 2024-12-10T06:53:43Z |
| publishDate | 2016-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of the International Association of Providers of AIDS Care |
| spelling | doaj.art-6f90b3927a794269aecb9001b27f96492022-12-22T01:58:28ZengSAGE PublishingJournal of the International Association of Providers of AIDS Care2325-95742325-95822016-01-011510.1177/2325957415594883Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United StatesMitch Dekoven MHSA0Charles Makin BSPharm, MS, MBA, MM1Samantha Slaff MS2Michael Marcus MAS3Eric M. Maiese PhD4IMS Health, Fairfax, VA, USAIMS Health, Fairfax, VA, USAYoh Services LLC, Philadelphia, PA, USAIMS Health, Fairfax, VA, USAMerck Sharp & Dohme Corp, Whitehouse Station, NJ, USAObjective: To estimate health care costs associated with medical events identified as antiretroviral therapy (ART)-attributable adverse events (AEs). Methods: During September 2006 to June 2012, adults with ≥1 HIV International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code (042/V08), ≥1 claim for ART prescription (March 2007-June 2011; index date), and continuous health plan enrollment for ≥6 months pre- and ≥12 months postindex were included (IMS’ PharMetrics Plus Health Plan Claims Database). Patients with events of interest/ART claim during preindex period or with pregnancy/hepatitis C virus diagnosis/hepatitis B virus/cancer/tuberculosis during the study period were excluded. Postindex medical events were defined as first diagnosis code of event with ART claim ≤60 days prior to start of the event. Results: Differences in median total all-cause health care costs observed for diabetes/insulin resistance management (US$14 547 median all-cause health care costs during time periods identified as diabetes/insulin resistance medical events versus US$11 237 without diabetes/insulin resistance events; P = .0021), lipid disorders (US$12 825 versus US$10 033; P = .0004), and renal disorders (US$1389 versus US$0; P < .0001). Discussion/Conclusion: Health care costs of ART AEs should be key consideration for payers/providers in HIV management.https://doi.org/10.1177/2325957415594883 |
| spellingShingle | Mitch Dekoven MHSA Charles Makin BSPharm, MS, MBA, MM Samantha Slaff MS Michael Marcus MAS Eric M. Maiese PhD Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States Journal of the International Association of Providers of AIDS Care |
| title | Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States |
| title_full | Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States |
| title_fullStr | Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States |
| title_full_unstemmed | Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States |
| title_short | Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States |
| title_sort | economic burden of hiv antiretroviral therapy adverse events in the united states |
| url | https://doi.org/10.1177/2325957415594883 |
| work_keys_str_mv | AT mitchdekovenmhsa economicburdenofhivantiretroviraltherapyadverseeventsintheunitedstates AT charlesmakinbspharmmsmbamm economicburdenofhivantiretroviraltherapyadverseeventsintheunitedstates AT samanthaslaffms economicburdenofhivantiretroviraltherapyadverseeventsintheunitedstates AT michaelmarcusmas economicburdenofhivantiretroviraltherapyadverseeventsintheunitedstates AT ericmmaiesephd economicburdenofhivantiretroviraltherapyadverseeventsintheunitedstates |